ABSTRACT ON ASLAN PHARMACEUTICALS’ VARLITINIB ACCEPTED FOR POSTER PRESENTATION AT ESMO ASIA CONGRESS 2019
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on its lead candidate, varlitinib, has been accepted for poster presentation at the ESMO Asia Congress 2019 in Singapore on 22 November – 24 November.
Data comparing the therapeutic response between varlitinib plus capecitabine and lapatinib plus capecitabine by analyzing the changes of tumor volume per tumor location in patients with HER2-positive metastatic breast cancer after trastuzumab therapy will be presented.
The abstract (Abstract #681), titled ‘The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumor location’, will be available online at https://www.esmo.org/Conferences/ESMO-Asia-Congress-2019 on 19 November, 17:05 CEST.
About varlitinib (ASLAN001)
Varlitinib (ASLAN001) is a highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4. These receptors can be mutated or overexpressed in many tumours, which can cause excessive proliferative activity and uncontrolled growth. Therefore, by inhibiting the activation of the HER receptors, varlitinib could inhibit proliferation and control tumour growth. Varlitinib has been granted orphan drug designation in the United States for gastric cancer and cholangiocarcinoma, a sub-type of biliary tract cancer, and was awarded orphan drug designation for the treatment of biliary tract cancer by the Ministry of Food and Drug Safety in South Korea.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497) is a clinical-stage oncology and immunology focused biopharma company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialisation, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN’s clinical portfolio is comprised of three product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL. For additional information please visit www.aslanpharma.com.
- ASLAN Pharmaceuticals
- ASLAN Pharmaceuticals